Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Reiterated by Cantor Fitzgerald

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “neutral” rating reiterated by research analysts at Cantor Fitzgerald in a research report issued on Friday, Benzinga reports. They currently have a $220.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential downside of 22.62% from the company’s previous close.

A number of other equities analysts also recently issued reports on the stock. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. TD Cowen lifted their price target on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Raymond James increased their price objective on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. Six equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $285.62.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $284.32 on Friday. The firm has a market capitalization of $35.96 billion, a price-to-earnings ratio of -106.09 and a beta of 0.39. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $287.55. The business has a 50 day simple moving average of $269.10 and a two-hundred day simple moving average of $212.11.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. During the same quarter last year, the firm earned ($2.21) EPS. The business’s revenue was up 107.0% on a year-over-year basis. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post -2.73 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $19,829,070. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Yvonne Greenstreet sold 15,148 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,829,070. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares in the company, valued at $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,398 shares of company stock worth $13,595,460. Insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ALNY. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after acquiring an additional 287,064 shares during the period. Capital Research Global Investors lifted its stake in shares of Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Alnylam Pharmaceuticals by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after buying an additional 201,784 shares during the period. AQR Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 92.5% in the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock worth $65,862,000 after buying an additional 130,482 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $18,886,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.